Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S281700, C548S182000, C549S417000
Reexamination Certificate
active
06878727
ABSTRACT:
Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus
REFERENCES:
patent: 4591583 (1986-05-01), Helgstrand et al.
patent: 5846964 (1998-12-01), Ozeki
patent: 6169181 (2001-01-01), Romines et al.
patent: 6174868 (2001-01-01), Anderson et al.
patent: 6340690 (2002-01-01), Bachand et al.
patent: WO 0208198 (2002-01-01), None
Baginski, S. et. al., “Mechanism of Action of a Pestivirus Antiviral Compound,”Proc. Natl. Acad. Sci. USA,2000, 7981-7986, vol. 97, No. 14.
Bagshawe,K. et. al., “Antibody-Directed Enzyme Prodrug Therapy: A Review,”Drug. Development Research,1995, 220-230, 34.
Bartenschlager, R. et al., “Molecular Targets In Inhibition Of Hepatitis C Virus Replication”Antiviral Chemistry&Chemotherapy1997, pp. 281-301, vol. 8, No. 4.
Bartenschlager, R. et al., “Nonstructural Protein 3 Of The Hepatitis C Virus Encodes A Serine-Type Proteinase Required For Cleavage At The NS3/4 And NS4/5 Junctions”Journal of Virology,Jul. 1993, pp. 3835-3844, vol. 67, No. 7.
Bertolini, G. et al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Lefluonomide, a Potent Immunosuppressive Drug,”Journal of Med. Chem.,1997, 2011-2016, 40.
Bodor, N, “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems,”Advances in Drug Research.,1984, 224-331, 13.
Brown, E. et al., “Secondary Structure Of The 5′Nontranslated Regions of Hepatitis C Virus And Pestivirus Genomic RNAs”Nucleic Acids Research1992, pp. 5041-5045, vol. 20, No. 19.
Bukh, J. et al., “Sequence Analysis of the 5′Noncoding Region of Hepatitis C Virus,”Proc. National Academy of Science USA,1992, 4942-4946, 89.
Bungaard, H. et al. ,Design of Prodrugs,1985, Elsevier Press.
Choo, Q. et al., “Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome,”Science,1989, 359-362, 244.
Cuthbert, J., “Hepatitis C: Progress and Problems”Clinical Microbiology Reviews,Oct. 1994, pp. 505-532, vol. 7, No. 4.
Dear, G.J. et al., “Mass Directed Peak Selection, an Efficient Method of Drug Metabolite Identification Using Directly Coupled Liquid Chromatography-Mass Spectrometry-Nuclear Magnetic Resonance Spectroscopy,”Journal of Chromatography B,2000, 281-293, 748.
Earl, R. et al.,, “The Preparation of 1(1H)-Pyridinones and 2,3-Dihydro-5(1H)-Indolizinones via Transition Metal Mediated Cocylization of Alkynes and Isocyanates. A Novel Construction of the Antitumor Agent Camptothecin,”Journal of Organic Chemistry,1984, 4786-4800, 49.
Ferrari, E. et al., “Characterization of Soluble Hepatitis C Virus RNA-Dependent RNA Polymerase Expressed inEscherichia Coli,” Journal of Virology,1999, 1649-1654, vol. 73, No. 2.
Friis, G. et al.,Design and Application of Prodrugs, Drug Design and Development,1991, Harwood Academic Publishers.
Grakoui, A. et al., “Expression And Identification Of Hepatitis C Virus Polyprotein Cleavage Products”Journal Of Virology,Mar. 1993, pp. 1385-1395, vol. 67, No. 3.
Hajimorad, et al., “Some Observations On The Binding Properties Of Alfalfa Mosaic Virus To Polystyrene And It's Significance To Indirect ELISA” Arch Virol., 1991, pp. 219-235, vol. 117.
Hijikata, M. et al., “Gene Mapping of the Putative Structural Region of the Hepatitis C Virus Genome by In Vitro Processing Analysis,”Proc. Natl. Acad. Science USA,1991, 5547-5551, 88.
Hwang, S. et al., “Hepatitis C Virus NS5B Protien Is A Membrane-Associated Phosphoprotein With A Predominantly Perinuclear Localization,”Virology,1997, pp. 439-446, vol. 227.
Ishii, K. et. al., “Expression of Hepatitis C Virus NS5B Protein: Characterization of Its RNA Polymerase Activity and RNA Binding,”Hepatology,1999, 1227-1235, vol. 29, No. 4.
Jamison, D. et al.,World Health Organization,1998, 514-517, 351.
Kim, J. et. al., “Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide,”Cell,1996, 343-355, 87.
Kim., J. et. al., “Hepatitis C Virus NS3 RNA Helicase Domain with a Bound Oligonucleotide: The Crystal Structure Provides Insights into the Mode of Unwinding,”Structure,1998, 89-100, 6.
Kolykhalov, et. al., “Identification of a Highly Conserved Sequence Element at the 3′ Terminus of Hepatitis C Virus Genome RNA,”Journal of Virology,1996, 3363-3371, vol. 70, No. 9.
Kunz, K., “A Simple and Convenient Synthesis of 5-Substituted Benzoxazoles,”Organic Preparations and Procedures, Int.,1990, 613-618, vol. 22, No. 5.
Lin, et al., “Processing in the Hepatitis C Virus E2-NS2 Region: Identification of p7 and Two Distinct E2-Specific Products with Different C Termini,” Journal of Virology, 1994, 5063-5073, vol. 68, No. 8.
Lohmann, V. et. al., “Biochemical and Kinetics Analyses of NS5B RNA-Dependent RNA Polymerase of the Hepatitis C Virus,”Virology,1998, 108-118, 249.
Lohmann, V. et. al., “Biochemical Properties of Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase and Identification of Amino Acid Sequence Motifs Essential for Enzymatic Activity,”Journal of Virology,1997, 8416-8428, vol. 71, No. 11.
Love, R. et. al., “The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site.,”Cell,1996, 331-342, 87.
Marcellin, P. et. al., “Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-alpha Therapy,”Annals of Internal Medicine,1997, 875-881, 127.
May, Q. et al., “Recent Advances In Prevention And Treatment Of Hepatitis C Virus Infections,”Process in Drug Research,2000, pp. 1-32, 55.
McKillop, A. et. al., “Reaction of Benzothiazole and Substituted Benzothiazoles with Dimethyl Acetylenedicarboxylate. A Novel Heterocyclic Ring Transformation,”Journal of Organic Chemistry,1876, 1328-1331, vol. 41 No. 8.
Miller, R. et. al., “Hepatitis C Virus Shares Amino Acid Sequence Similarity with Pestiviruses and Flaviviruses as well as Members of Two Plant Virus Supergroups,”Proc. Natl. Academy of Science USA,1990, 2057-2061, 87.
Poch, O. et al., “Identification Of Four Conserved Motifs Among The RNA-Dependent Polymerase Encoding Elements”The EMBO Journal,1989, pp. 3867-3874, vol. 8, No. 12.
Prox, et. al., “Rapid Structure Elucidation of Drug Metabolites by Use of Stable Isotopes,”Xenobiotica,1973, 103-112, vol. 3 No. 2.
Rink, Hans, “Solid-Phase Synthesis Of Protected Peptide Fragments Using A Trialkoxy-Diphenyl-Methylester Resin.” Tetrahedron Letters, 1987, pp. 3787-3790, vol. 28, No. 33.
Shan, D. et. al., “Prodrug Strategies Based on Intramolecular Cyclization Reactions,”Journal of Pharmaceutical Sciences,1997, 765-767, vol. 86, No. 7.
Simmonds, P. et. al., Classification Of Hepatitis C Virus Into Six Journal of Gen. Virology, 1993, 2391-2399, 74.
Spraul, M. et. al., “Liquid Chromatography Coupled With High-Field Proton NMR For Profiling Human Urine For Endogenous Compounds and Drug Metabolites”Journal of Pharmaceutical&Biomedical Analysis,1992, 601-605, vol. 10 No. 8.
Tanaka, T. et. al., “Structure of the 3′ Terminus of the Hepatitis C Virus Genome,”Journal of Virology,1996, 3307-3312, vol. 70, No. 5.
Weiner, A. et al., “Evidence For Immune Selection Of Hepatitis C Virus (HCV) Putative Envelope Glycoprotein Variants: Potential Role In Chronic HCV Infections,”Proc. Natl. Acad. Sci. USA,Apr. 1992, pp. 3468-3472, vol. 89.
Weiner, A. et al., “Variable And Hypervariable Domains Are Found In The Regiosn Of HCV Corresponding To The Flavivirus Envelope A
Borchardt Allen J.
Goble Michael Paul
Agouron Pharmaceuticals , Inc.
Hutchinson Keith D.
Richardson Peter C.
Saeed Kamal
Zielinski Bryan C.
LandOfFree
Inhibitors of hepatitis C virus RNA-dependent RNA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of hepatitis C virus RNA-dependent RNA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of hepatitis C virus RNA-dependent RNA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3389539